Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Increased survival in NSCLC: new considerations

Federico Cappuzzo • 11 Apr 2018
ELCC 2018
Lung Cancer Non-Small Cell Lung Cancer Pembrolizumab

Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Cappuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, talks about how overall survival has improved in patients with non-small cell lung cancer (NSCLC) and the problems associated with this increase in survival.

More from Federico Cappuzzo

1:25
Current treatment recommendations and future directions for EGFR-mutant NSCLC
Federico Cappuzzo • 7 Aug 2022
1:06
FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
Federico Cappuzzo • 7 Aug 2022
1:18
MRD status in lung cancer
Federico Cappuzzo • 7 Aug 2022
1:06
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
Federico Cappuzzo • 7 Aug 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals